Searched for
VIATRIS ACQUISITION
The alchemist of Bengaluru: Kiran Mazumdar-Shaw began from a garageKiran Mazumdar-Shaw has named her niece Claire Mazumdar as successor, setting up a gradual leadership transition at Biocon. A pioneer who b...- Sun Pharma shares rally 9% in two days after $12-bn Organon deal. Here's what Morgan Stanley, other brokerages saySun Pharmaceutical Industries' shares surged nearly 9% after announcing the $11.75 billion acquisition of Organon & Co., a global leader in...
- S&P Global upgrades Biocon Biologics credit rating To 'BB+'Biocon Biologics has received a credit rating upgrade from S&P Global Ratings. The company's long-term issuer credit rating is now 'BB+' wi...
- Biocon betting big on new product launches for growthBiocon aims to grow through new product launches in generics and biosimilars, bolstered by the Viatris acquisition. This strategy integrate...
- Biocon Biologics raises $300 million for debt refinancingThe loan was priced at 175 basis points above the three-month secured overnight funding rate (SOFR), which was trading at 4.59%. That pegs ...
- Biocon Biologics is planning to raise $950 million through overseas bondsBiocon Biologics plans to raise $950 million through overseas bond sales to refinance a significant portion of its $1.2-billion debt from a...
- Biocon Biologics to raise debt of Rs 4,500 crore for Viatris PayoutBiocon Biologics plans to raise ₹4,500 crore with HSBC and MUFG's aid for a $175 million Aflibercept option. Previous funding by Kotak and ...
- Kotak Alt invests Rs 1445 crore for the acquisition of Viatris' API business by Matrix PharmaKotak Alternate Asset Managers has announced a Rs 1,445 crore investment in the acquisition of Viatris' active pharmaceutical ingredient (A...
- Edelweiss fund to back Matrix Lab founder's buyout of Viatris API bizKotak is lending $150 million (₹1,250 crore) under a mezzanine debt facility to Prasad at 18-20% and arranging an additional $300 million f...
- Kotak Fund to part finance matrix lab founder's Viatris buyThe fund plans to provide a $150 million mezzanine debt facility at 18-20% and arrange another $300 million from other lenders to finance t...
- Biocon Biologics completes integration of Viatris' Europe biosimilar businessBiocon Biologics on Thursday said it has completed the integration of the acquired biosimilar business from Viatris Inc in 31 European coun...
- Kotak Fund to invest ₹1,600 crore in Nimmagadda Prasad's API businessKotak Strategic Situations Fund (KSSF) plans to invest around ₹1,600 crore in the active pharmaceutical ingredients (API) business acquired...
- Biocon raises $129 million from Kotak to fund biosimilars dealIndia's Kotak Mahindra Group asset management arm said on Wednesday it will invest 10.70 billion rupees ($129 million) in Biocon Ltd to hel...
- Biocon Biologics has comprehensive plan to integrate Viatris business: Shreehas Tambe, Biocon Biologics"There are several other discussions that we have been having with private equity investors who are interested in making an investment in B...
- Kiran Mazumdar Shaw on Viatris acquisition, R&D spend & Q3 result“The highest R&D spends will always happen in biologics because the highest cost of R&D spend is in clinical trials. As we move forward, th...
- Biocon Biologics expects big gains from integration of Viatris business, SII dealBiocon Biologics in March entered into a definitive agreement to acquire Viatris' biosimilars assets for $3.34 billion. It will pay Viatris...
- Biocon Biologics to raise $1.2 billion overseas loan for Viatris dealBiocon Biologics, a unit of Biocon, is raising $1.2 billion via an offshore loan with the pharmaceutical company likely appointing HSBC, MU...
- Viatris deal pinches Biocon, but may prove a good betThe $3.3-billion acquisition - that includes $2.3 billion cash and a 12.9% equity stake in BBL - stands at over half of the market cap of B...
- Biocon arm to buy US company Biosimilar biz for $3.34 billionBiocon Biologics (BBL) will get the global biosimilar business of Viatris in developed and emerging markets, with an estimated revenue of $...
- Biocon Biologics acquires Viatris' biosimilar business for $3.34 billionBBL said the cash payment of $2 billion to be funded by $800 million raised through equity infusion in BBL and the remainder to be funded b...
Load More
